Cadrenal Therapeutics (CVKD) Registration Filing summary

Company overview and business model

• Focuses on developing tecarfarin, a novel Vitamin K Antagonist (VKA) anticoagulant for patients with implanted cardiac devices or rare cardiovascular conditions where current therapies are inadequate.

• Tecarfarin is designed to offer safer, more effective anticoagulation than warfarin, with fewer drug interactions and improved outcomes for patients with LVADs, ESKD, and AFib.

• Holds orphan drug and fast-track designations from the FDA for specific indications, and has completed 11 clinical trials involving over 1,000 individuals.

• Targets a market segment underserved by current oral anticoagulants, especially where DOACs are contraindicated.

Financial performance and metrics

• Reported an accumulated deficit of $21.5 million as of September 30, 2024, and a net loss of $6.46 million for the nine months ended September 30, 2024.

• Existing cash and equivalents are expected to meet anticipated needs for the next twelve months, but additional capital will be required for long-term objectives and the pivotal Phase 3 trial.

• Recent financing activities include a $4.7 million warrant exercise and $5.1 million raised through at-the-market offerings in Q3 and October 2024.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; proceeds from warrant exercises will be used for general corporate purposes, including operating expenses, R&D, the pivotal Phase 3 trial, working capital, partnering, and potential acquisitions.

• Management retains broad discretion over allocation of proceeds from warrant exercises.